COCCO, CLAUDIO
 Distribuzione geografica
Continente #
NA - Nord America 400
EU - Europa 306
AS - Asia 112
Totale 818
Nazione #
US - Stati Uniti d'America 397
GB - Regno Unito 133
CN - Cina 90
SE - Svezia 53
FR - Francia 29
IE - Irlanda 25
DE - Germania 16
FI - Finlandia 14
RU - Federazione Russa 13
SG - Singapore 11
IT - Italia 10
KR - Corea 8
UA - Ucraina 7
BE - Belgio 3
CA - Canada 3
AT - Austria 1
CH - Svizzera 1
IN - India 1
JP - Giappone 1
NL - Olanda 1
TR - Turchia 1
Totale 818
Città #
Southend 108
Chandler 83
Jacksonville 56
Houston 47
Ann Arbor 35
Dublin 25
Woodbridge 25
Ashburn 23
Beijing 18
Lancaster 12
Lawrence 11
Princeton 11
Nanjing 9
Wilmington 9
Jinan 8
Seoul 8
Singapore 8
Hebei 7
Boardman 6
Detroit 6
Nanchang 6
Jiaxing 5
Tianjin 5
Verona 5
New York 4
Taiyuan 4
Brussels 3
Cascia 3
Dearborn 3
Leipzig 3
Fuzhou 2
Guangzhou 2
Haikou 2
Hangzhou 2
Helsinki 2
Phoenix 2
Shenyang 2
Toronto 2
Zhengzhou 2
Auburn Hills 1
Bilgi 1
Buffalo 1
Calgary 1
Changsha 1
Chaoyang 1
Clearwater 1
Cuddalore 1
Edinburgh 1
Fairfield 1
Falkenstein 1
Fushan 1
Kemerovo 1
Kent 1
Lanzhou 1
Los Angeles 1
Riva 1
San Francisco 1
Seattle 1
Taizhou 1
Tokyo 1
Vienna 1
Washington 1
Zurich 1
Totale 598
Nome #
Follicle-Stimulating Hormone and the Pituitary-Testicular-Prostate Axis at the Time of Initial Diagnosis of Prostate Cancer and Subsequent Cluster Selection of the Patient Population Undergoing Standard Radical Prostatectomy 102
Is it possible to use the identification of neutrophil gelatinase- associated lipocalin (NGAL) in the evaluation of bisphosphonates nephrotoxicity? [E' possibile utilizzare la determinazione della lipocalina associata alla gelatinasi dei neutrofili (NGAL) nella valutazione della nefrotossicità da bisfosfonati?] 93
Investigative clinical study on prostate cancer part VIII: prolactin hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy. 84
Investigative clinical study on prostate cancer Part V: Luteinizing hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population. 82
Investigative clinical study on prostate cancer part VI: Follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population. 76
Investigative clinical study on prostate cancer part VII: prolactin and the pituitary-testis-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population. 73
Investigative clinical study on prostate cancer part IX and X: estradiol and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy 69
DEFINITION OF UPPER REFERENCE LIMIT FOR THYROID PEROXIDASE AUTOANTIBODIES ACCORDING TO NACB GUIDELINES: COMPARISON OF SEVEN DIFFERENT AUTOMATED METHODS. Part B (in : Reference ranges, standardization and decision levels) 69
DEFINITION OF UPPER REFERENCE LIMIT FOR THYROID PEROXIDASE AUTOANTIBODIES ACCORDING TO NACB GUIDELINES: COMPARISON OF FIVE DIFFERENT AUTOMATED METHODS. PART A (in Reference ranges, standardization and decision levels) 64
Role of CA 15-3 to guide therapy in metastatic breast cancer [Il ruolo di CA 15-3 nel monitoraggio della terapia nel carcinoma mammario metastatico] 62
Choosing wisely: la lista del gruppo di studio Endocrinologia e Malattie del Metabolismo della Società Italiana di Patologia Clinica e Medicina di Laboratorio 57
Totale 831
Categoria #
all - tutte 2.867
article - articoli 2.350
book - libri 0
conference - conferenze 517
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.734


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202075 0 0 0 7 7 11 21 4 3 7 6 9
2020/202172 3 17 7 9 6 10 2 5 0 1 9 3
2021/2022118 12 36 0 23 0 7 2 6 2 2 4 24
2022/2023196 20 17 23 26 20 41 3 17 16 1 8 4
2023/202497 4 14 9 5 16 15 1 7 0 11 10 5
2024/202513 9 4 0 0 0 0 0 0 0 0 0 0
Totale 831